Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Scientists at École Polytechnique Fédérale de Lausanne (EPFL) have developed a small laboratory-in-a-box capable of housing and feeding a colony of C. elegans nematodes (roundworms) and testing the…
With the aid of single-cell sequencing technology, researchers at Harvard Medical School have mapped the beginnings of the biological development of both zebrafish and frogs from a single-cell…
Different types of movement disorders are difficult to distinguish due to many patients experiencing similar symptoms. Stephen Stahl, MD, discusses the differences between movement disorders, how they might…
PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain.
While there are not yet any standardized criteria for selecting candidates for deep brain stimulation (DBS) therapy, Kelvin L. Chou, MD, Co-Director of the STIM (Surgical Therapies Improving…
As patients begin displaying symptoms of Parkinson’s disease, it becomes increasingly difficult for them to express themselves verbally, and they may even become overwhelmed in loud social situations.…
